Dialysis News and Research

Latest Dialysis News and Research

First Edition: January 11, 2012

In today's headlines, the 26 states opposed to the health law have filed their Supreme Court arguments against the measure's Medicaid expansion.

11 Jan 2012

Shire, Janssen enter development and marketing agreement for Resolor

Shire plc, the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V.

11 Jan 2012

Shire acquires rights to develop and market Resolor in the U.S.

10 Jan 2012

Urinary biomarkers can diagnose AKI in high-risk patients

Acute kidney injury (AKI) has severe consequences, with a 25 to 80 percent risk of in-hospital death. Researchers have found a way to diagnose AKI using a urine test, enabling emergency departments to identify these high-risk patients when they first arrive at the hospital.

10 Jan 2012

Viewpoints: Protecting home health workers; Minn. plans cuts in health safety net

President Obama is proposing an adjustment to laws governing working conditions for approximately 2 million workers whose job is helping elderly and disabled people with such basic tasks as eating, caring for their wounds and doing physical therapy. Under the Obama proposal, these workers would have to be paid at least a minimum wage and overtime, bringing them under the aegis of the Fair Labor Standards Act. Some Republicans are opposed to the measure, complaining that it will be expensive and may hurt the people it is intended to help.

6 Jan 2012

Solar power can make hemodialysis treatments more environmentally friendly

Solar power can help offset high utility costs and make hemodialysis treatments more environmentally friendly, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

6 Jan 2012

Pharmalink raises SEK 35 million to further advance Nefecon and Busulipo

Pharmalink AB, today announces it has raised SEK 35 million through a rights issue of new shares to the Company's existing shareholders, including Industrifonden.

4 Jan 2012

Chart trends for bone and mineral metabolism in CKD

BioTrends Research Group, LLC has released findings from the 2011 ChartTrends: Bone and Mineral Metabolism in Chronic Kidney Disease report, the fifth in an on-going annual series. The study was conducted with 204 U.S. nephrologists who completed detailed chart reviews for 1,037 patients in CKD Stage 3, 4 and 5 not yet on dialysis.

29 Dec 2011

FMCNA recognizes 25 dialysis patients across the nation

The nation's leading network of dialysis facilities is recognizing more than 25 patients across the nation who will be 100 years or older in 2012 and are still leading healthy, fulfilling lives without their kidney function.

26 Dec 2011

Ariz. eyeing first budget surplus in four years; Wis. study finds low Medicare, Medicaid rates shift costs

Here's something Arizona hasn't seen in a while: a state budget surplus. Estimates range from $416 million to as much as $650 million when the new budget year starts in July. ... "We'll fund population increases in K-12, AHCCCS (the state's Medicaid program) and prisons," said House Appropriations Chairman John Kavanagh, who's starting his fourth year as budget chairman.

20 Dec 2011

ASN joins ABIM Foundation's Choosing Wisely campaign

The American Society of Nephrology (ASN), the world's leading kidney organization, joins the American Board of Internal Medicine (ABIM) Foundation, eight other leading national medical specialty societies and Consumer Reports in the Choosing Wisely campaign. This campaign will help physicians, patients and other health care professionals address overuse of health care resources in the United States.

15 Dec 2011

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Researchers uncover important source of inflammation for CKD

UC Irvine researchers have uncovered an important source of inflammation seen in people with chronic kidney disease, which is increasingly common due to the epidemic of obesity-related diabetes and hypertension.

14 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

Aethlon Hemopurifier can capture Nef protein exosomes linked with HIV

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome.

14 Dec 2011

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

ACE inhibitors, ARBs have different effects on heart health of dialysis patients

Two seemingly similar blood pressure-lowering drugs have different effects on the heart health of dialysis patients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

12 Dec 2011

Most patients with AKI do not see kidney specialists within a year

Most patients with an abrupt kidney injury that does not get better do not see a kidney specialist within a year, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

12 Dec 2011

Bluegrass Vascular commences enrollment in clinical study of Surfacer Inside-Out Access Catheter System

Bluegrass Vascular Technologies, a medical technology company focused on life-saving devices and methods for vascular access procedures, has announced patient enrollment in the first clinical study of its Surfacer Inside-Out Access Catheter System, a proprietary system that allows physicians to perform a novel "inside-out" approach to gain venous access.

9 Dec 2011